Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
AstraZeneca
Harvard Business School
McKesson
Merck

Last Updated: October 1, 2022

ZONTIVITY Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Zontivity, and when can generic versions of Zontivity launch?

Zontivity is a drug marketed by Xspire Pharma and is included in one NDA. There are two patents protecting this drug.

This drug has one hundred and sixty-four patent family members in thirty-seven countries.

The generic ingredient in ZONTIVITY is vorapaxar sulfate. Two suppliers are listed for this compound. Additional details are available on the vorapaxar sulfate profile page.

DrugPatentWatch® Generic Entry Outlook for Zontivity

Zontivity was eligible for patent challenges on May 8, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 23, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Summary for ZONTIVITY
International Patents:164
US Patents:2
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 2
Raw Ingredient (Bulk) Api Vendors: 84
Clinical Trials: 5
Patent Applications: 475
Drug Prices: Drug price information for ZONTIVITY
What excipients (inactive ingredients) are in ZONTIVITY?ZONTIVITY excipients list
DailyMed Link:ZONTIVITY at DailyMed
Drug patent expirations by year for ZONTIVITY
Drug Prices for ZONTIVITY

See drug prices for ZONTIVITY

DrugPatentWatch® Estimated Generic Entry Opportunity Date for ZONTIVITY
Generic Entry Date for ZONTIVITY*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ZONTIVITY

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Vanderbilt UniversityPhase 4
Vanderbilt University Medical CenterPhase 4
Merck Sharp & Dohme Corp.Phase 4

See all ZONTIVITY clinical trials

Pharmacology for ZONTIVITY

US Patents and Regulatory Information for ZONTIVITY

ZONTIVITY is protected by two US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of ZONTIVITY is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting ZONTIVITY

Thrombin receptor antagonists
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS

Thrombin receptor antagonists
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION (MI) OR WITH PERIPHERAL ARTERIAL DISEASE (PAD)

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Xspire Pharma ZONTIVITY vorapaxar sulfate TABLET;ORAL 204886-001 May 8, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Xspire Pharma ZONTIVITY vorapaxar sulfate TABLET;ORAL 204886-001 May 8, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ZONTIVITY

See the table below for patents covering ZONTIVITY around the world.

Country Patent Number Title Estimated Expiration
Japan 2004503551 See Plans and Pricing
Hong Kong 1123302 MANUFACTURE OF TRICYCLIC THROMBIN RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM See Plans and Pricing
Singapore 164279 TRICYCLIC THROMBIN RECEPTOR ANTAGONISTS See Plans and Pricing
Japan 2010132710 TRICYCLIC THROMBIN RECEPTOR ANTAGONIST See Plans and Pricing
Luxembourg 92759 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ZONTIVITY

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1495018 CA 2015 00037 Denmark See Plans and Pricing PRODUCT NAME: VORAPAXAR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING VORAPAXARSULPHATE; REG. NO/DATE: EU/1/14/976/001-06 20150119
1495018 1590037-6 Sweden See Plans and Pricing PRODUCT NAME: VORAPAXAR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF; REG. NO/DATE: EU/1/14/976/001 20150121
1495018 PA2015027,C1495018 Lithuania See Plans and Pricing PRODUCT NAME: VORAPAKSARAS; REGISTRATION NO/DATE: EU/1/14/976/001 - EU/1/14/976/006 20150119
1495018 2015/035 Ireland See Plans and Pricing PRODUCT NAME: VORAPAXAR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF; REGISTRATION NO/DATE: EU/1/14/976/001-006 20150119
1495018 218 50011-2015 Slovakia See Plans and Pricing PRODUCT NAME: VORAPAXARIUMSULFAT; REGISTRATION NO/DATE: EU/1/14/976/001 - EU/1/14/976/006 20150121
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Boehringer Ingelheim
McKesson
Moodys
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.